Log In
Print
BCIQ
Print
Print this Print this
 

Ozanezumab (1223249)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHumanized monoclonal antibody (mAb) against reticulon 4 NOGO
Molecular Target Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B)
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase II
IndicationAmyotrophic lateral sclerosis (ALS)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today